SPRUCE BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7 USD | -0.14% |
|
-0.06% | -76.11% |
| 03-15 | North American Morning Briefing : Inflation -2- | DJ |
| 03-14 | Top Midday Decliners | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 564.3 | 104.6 | 25.86 | 119.3 | 28.81 | - | - |
| Enterprise Value (EV) 1 | 411.7 | 20.55 | -48.31 | 119.3 | -15.29 | -60.69 | -103.4 |
| P/E ratio | -4.93 x | -2.46 x | -0.56 x | -2.36 x | -0.6 x | -0.7 x | -0.72 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | 11.8 x | 6.26 x | 22.2 x | 12.5 x |
| EV / Revenue | - | - | - | 11.8 x | -3.32 x | -46.7 x | -45 x |
| EV / EBITDA | -14,011,550 x | -489,413 x | 1,023,258 x | - | - | - | - |
| EV / FCF | -14,918,977 x | -571,431 x | 1,158,691 x | - | - | - | - |
| FCF Yield | -0% | -0% | 0% | - | - | - | - |
| Price to Book | - | 0.94 x | -0.17 x | - | - | - | - |
| Nbr of stocks (in thousands) | 23,214 | 23,463 | 23,560 | 40,711 | 41,153 | - | - |
| Reference price 2 | 24.31 | 4.460 | 1.097 | 2.930 | 0.7000 | 0.7000 | 0.7000 |
| Announcement Date | 22/03/21 | 14/03/22 | 16/03/23 | 13/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 10.09 | 4.604 | 1.3 | 2.3 |
| EBITDA | -29.38 | -42 | -47.21 | - | - | - | - |
| EBIT 1 | -29.42 | -42.07 | -47.28 | -51.99 | -48.03 | -61.02 | -68.16 |
| Operating Margin | - | - | - | -515.34% | -1,043.18% | -4,694.21% | -2,963.6% |
| Earnings before Tax (EBT) 1 | -29.54 | -42.29 | -46.18 | -47.92 | -49.69 | -60.7 | -73.77 |
| Net income 1 | -29.54 | -42.29 | -46.18 | -47.92 | -49.78 | -60.4 | -70.98 |
| Net margin | - | - | - | -474.96% | -1,081.14% | -4,646.06% | -3,086% |
| EPS 2 | -4.930 | -1.810 | -1.960 | -1.240 | -1.175 | -1.005 | -0.9775 |
| Free Cash Flow | -27.59 | -35.97 | -41.69 | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 22/03/21 | 14/03/22 | 16/03/23 | 13/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | 1.964 | 2.165 | 3.073 | 2.887 | 1.158 | 1.229 | 1.301 | 0.9166 |
| EBITDA | -11.38 | -9.115 | - | -11.87 | -11.54 | -12.09 | - | - | - | - | - | - | - | - |
| EBIT 1 | -11.4 | -9.135 | -11.73 | -11.88 | -11.56 | -12.11 | -13.2 | -13.97 | -13.66 | -11.16 | -11.96 | -11.25 | -11.14 | -13.69 |
| Operating Margin | - | - | - | - | - | - | -672.05% | -645.36% | -444.45% | -386.7% | -1,032.94% | -914.92% | -856.29% | -1,493.34% |
| Earnings before Tax (EBT) 1 | -11.45 | -9.184 | -11.76 | -11.87 | -11.4 | -11.14 | -12.79 | -12.82 | -12.35 | -9.95 | -11.57 | -10.86 | -10.82 | -16.46 |
| Net income 1 | -11.45 | -9.184 | -11.76 | -11.87 | -11.4 | -11.14 | -12.79 | -12.82 | -12.35 | -9.95 | -12.45 | -11.71 | -11.57 | -14.07 |
| Net margin | - | - | - | - | - | - | -651.27% | -592.33% | -402.02% | -344.65% | -1,075.14% | -952.49% | -889.55% | -1,534.96% |
| EPS 2 | -0.4900 | -0.3900 | -0.5000 | -0.5100 | -0.4800 | -0.4700 | -0.4000 | -0.3200 | -0.3000 | -0.2300 | -0.3050 | -0.2850 | -0.2717 | -0.3250 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 15/11/21 | 14/03/22 | 11/05/22 | 10/08/22 | 10/11/22 | 16/03/23 | 15/05/23 | 14/08/23 | 13/11/23 | 13/03/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | 153 | 84.1 | 74.2 | - | 44.1 | 89.5 | 132 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | -27.6 | -36 | -41.7 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | 4.740 | -6.350 | - | - | - | - |
| Cash Flow per Share | -4.590 | -1.540 | -1.770 | - | - | - | - |
| Capex | 0.07 | 0.09 | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 22/03/21 | 14/03/22 | 16/03/23 | 13/03/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
0.7
USD
Average target price
2.75
USD
Spread / Average Target
+292.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -76.11% | 28.81M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- SPRB Stock
- Financials Spruce Biosciences, Inc.
